Brainsway announces CMS published first coverage recommendation for TMS

BrainsWay announced today that the Clinical TMS Society, CTMSS, an influential medical society dedicated to supporting the clinical practice, research, and access to transcranial magnetic stimulation, TMS, has published the first coverage recommendations for smoking addiction treatment using TMS. BrainsWay Deep TMS is the only TMS technology to have received FDA clearance for the treatment of smoking addiction. “We are encouraged by the ongoing efforts of the Clinical TMS Society to drive favorable coverage for TMS around the world,” said Aron Tendler, MD, Chief Medical Officer of BrainsWay. “Nicotine use continues to be the leading cause of preventable death across the globe, and based our data, Deep TMS can be a beneficial solution for those looking to quit without prior success.”